Free Trial
→ Your trading day could end at 11 AM (From ProsperityPub) (Ad)

Royalty Pharma Q4 2024 Earnings Report

Royalty Pharma logo
$33.42 +0.09 (+0.27%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Royalty Pharma EPS Results

Actual EPS
$1.15
Consensus EPS
$0.99
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Royalty Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$743.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Royalty Pharma Announcement Details

Quarter
Q4 2024
Date
2/11/2025
Time
Before Market Opens

Conference Call Resources

Royalty Pharma Earnings Headlines

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
February 19 at 9:54 AM | msn.com
Royalty Pharma plc (RPRX) Stock Forecasts
February 14, 2025 | ca.finance.yahoo.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Royalty Pharma: Delivering Growth With A Positive Story Ahead
February 12, 2025 | seekingalpha.com
Royalty Pharma plc: Royalty Pharma Announces R&D Funding Collaboration With Biogen
February 12, 2025 | finanznachrichten.de
Royalty Pharma plc (RPRX): A Cheap Biotech Stock to Invest In Now
February 12, 2025 | msn.com
See More Royalty Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email.

About Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

View Royalty Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles